<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="cebpa-aml" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">cebpa-aml</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">CEBPA-</italic>Associated Familial Acute Myeloid Leukemia (AML)</title>
        <alt-title alt-title-type="alt-title">Synonym: <italic toggle="yes">CEBPA</italic>-Dependent Familial Acute Myeloid Leukemia</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tawana</surname>
            <given-names>Kiran</given-names>
          </name>
          <degrees>MBChB, FRCPath</degrees>
          <aff>Barts Cancer Institute<break/>Queen Mary University of London<break/>London, United Kingdom</aff>
          <email>k.tawana@qmul.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fitzgibbon</surname>
            <given-names>Jude</given-names>
          </name>
          <degrees>BA, PhD</degrees>
          <aff>Barts Cancer Institute<break/>Queen Mary University of London<break/>London, United Kingdom</aff>
          <email>j.fitzgibbon@qmul.ac.uk</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2010-10-21" date-type="created">
          <day>21</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date iso-8601-date="2016-04-28" date-type="updated">
          <day>28</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="hrpt2" document-type="chapter">
<italic toggle="yes">CDC73</italic>-Related Disorders</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="charge" document-type="chapter">CHARGE Syndrome</related-object>
      <abstract id="cebpa-aml.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">CEBPA-</italic>associated familial acute myeloid leukemia (AML) is defined as AML in which a heterozygous germline <italic toggle="yes">CEBPA</italic> pathogenic variant is present in a family in which multiple individuals have AML. In contrast, sporadic <italic toggle="yes">CEBPA</italic>-associated AML is defined as AML in which a <italic toggle="yes">CEBPA</italic> pathogenic variant(s) is identified in leukemic cells but not in the non-leukemic cells. Too few individuals with <italic toggle="yes">CEBPA</italic>-associated familial AML have been reported to be certain about the natural history of the disease. In the majority of individuals, the age of onset of familial AML appears to be earlier than sporadic AML; disease onset has been reported in persons as young as age 1.8 years and older than age 45 years. The prognosis of <italic toggle="yes">CEBPA-</italic>associated familial AML appears to be favorable compared with sporadic <italic toggle="yes">CEBPA</italic>-associated AML. Individuals with <italic toggle="yes">CEBPA</italic>-associated familial AML who have been cured of their initial disease may be at greater risk of developing additional independent leukemic episodes in addition to the risk of relapse due to preexisting clones.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">CEBPA</italic>-associated familial AML is established by identification of a heterozygous germline <italic toggle="yes">CEBPA</italic> pathogenic variant in a specimen that contains only non-leukemic cells from an individual with AML, or by observing segregation of a shared germline <italic toggle="yes">CEBPA</italic> pathogenic variant across affected family members.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment usually includes cytarabine/anthracycline-based induction and cytarabine-based consolidation chemotherapy. Hematopoietic stem cell transplantation (HSCT) from a volunteer unrelated donor (VUD) or appropriately screened family member should be reserved for individuals failing to achieve remission following standard induction therapy or for disease recurrence. Whenever possible, persons with AML should be treated as part of a clinical trial protocol.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Similar to that for other types of AML (i.e., administration of blood products such as red blood cell and platelet transfusions as needed; treatment of infections with antibiotics; and use of prophylactic antibiotics and anti-fungal agents during periods of severe neutropenia).</p>
          <p><italic toggle="yes">Surveillance:</italic> Similar to that for other forms of AML. Because of the increased risk of leukemia recurrence in persons with familial AML, lifelong surveillance may be warranted.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Predisposition to <italic toggle="yes">CEBPA-</italic>associated familial AML is inherited in an autosomal dominant manner. Most individuals diagnosed with <italic toggle="yes">CEBPA</italic>-associated familial AML have had an affected parent who shares the germline pathogenic variant. Germline <italic toggle="yes">CEBPA</italic> pathogenic variants exhibit complete or near-complete penetrance for the development of AML in families reported to date. Each child of an affected individual has a 50% chance of inheriting the germline pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the germline <italic toggle="yes">CEBPA</italic> pathogenic variant in the family is known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="cebpa-aml.Diagnosis">
        <title>Diagnosis</title>
        <p>To date there are no universally accepted guidelines for the detection of germline pathogenic variants associated with acute myeloid leukemia (AML), although a useful algorithm has been proposed by <xref ref-type="bibr" rid="cebpa-aml.REF.nickels.2013.254">Nickels et al [2013]</xref>.</p>
        <sec id="cebpa-aml.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">CEBPA-</italic>associated familial AML <bold>should be suspected</bold> in individuals with the following clinical and supportive laboratory findings:</p>
          <p>
            <bold>Clinical findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with AML who also have a family history of AML</p>
            </list-item>
            <list-item>
              <p>Individuals who have developed AML at an early age (&#x0003c;50 years)</p>
            </list-item>
          </list>
          <p>
            <bold>Supportive laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Young individuals with AML whose leukemic cells have a pathogenic variant in both copies of <italic toggle="yes">CEBPA</italic></p>
            </list-item>
            <list-item>
              <p>Normal karyotype in leukemic cells</p>
            </list-item>
            <list-item>
              <p>A preponderance of French-American-British (FAB) Cooperative Group AML Classification subtypes M1 or M2 as established by morphologic analysis of peripheral blood or bone marrow blasts</p>
            </list-item>
            <list-item>
              <p>Auer rods seen in blasts (i.e., abnormal, needle-shaped or round, light blue or pink-staining inclusions found in the cytoplasm of leukemic cells)</p>
            </list-item>
            <list-item>
              <p>Aberrant CD7 expression on blasts as demonstrated by flow cytometry</p>
            </list-item>
          </list>
          <p>Note: A provisional diagnostic category of &#x0201c;AML with mutated <italic toggle="yes">CEBPA&#x0201d;</italic> was proposed in the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [<xref ref-type="bibr" rid="cebpa-aml.REF.arber.2008">Arber et al 2008</xref>]. This classification is primarily intended for sporadic AML and does not distinguish familial forms of disease or the presence of a pathogenic variant in one or both copies of <italic toggle="yes">CEBPA</italic>; only the latter have favorable prognostic significance in AML.</p>
          <p>For this <italic toggle="yes">GeneReview</italic>, the following definitions are used:</p>
          <p><bold><italic toggle="yes">CEBPA</italic>-associated familial AML</bold> is defined by the presence of a germline <italic toggle="yes">CEBPA</italic> pathogenic variant. Germline variants may be inherited across multiple generations or develop <italic toggle="yes">de novo</italic> in parental germ cells, prior to their transmission. Once inherited, they are present in every cell of an individual as part of their unique genetic make-up. Germline <italic toggle="yes">CEBPA</italic> pathogenic variants typically coincide with a family history of AML and the diagnosis is established by either of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Detection of a germline <italic toggle="yes">CEBPA</italic> pathogenic variant in a specimen that contains only non-leukemic cells from an individual with AML</p>
            </list-item>
            <list-item>
              <p>Detection of a shared germline <italic toggle="yes">CEBPA</italic> pathogenic variant in affected (and possibly asymptomatic) members of an AML pedigree</p>
            </list-item>
          </list>
          <p><bold>Sporadic <italic toggle="yes">CEBPA-</italic>associated</bold>
<bold>AML</bold> is defined as AML in which a somatic <italic toggle="yes">CEBPA</italic> pathogenic variant(s) is acquired in leukemic cells alone; these variants are absent in all of the individual&#x02019;s non-leukemic cells (see <xref ref-type="sec" rid="cebpa-aml.Molecular_Genetics">Molecular Genetics</xref>).</p>
        </sec>
        <sec id="cebpa-aml.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of <italic toggle="yes">CEBPA</italic>-associated familial AML <bold>is established</bold> in a proband with a confirmed germline <italic toggle="yes">CEBPA</italic> pathogenic variant (see <xref ref-type="table" rid="cebpa-aml.T.molecular_genetic_testing_us">Table 1</xref>). Because <italic toggle="yes">CEBPA</italic>-associated familial AML develops from cells that have a pathogenic (cancer-predisposing) variant in both copies of <italic toggle="yes">CEBPA,</italic> leukemic cells frequently demonstrate both a germline and a somatic <italic toggle="yes">CEBPA</italic> variant at AML diagnosis. The germline pathogenic variant is typically a frameshift located in the <italic toggle="yes">CEBPA</italic> region encoding the N-terminal C/EBP&#x003b1; protein, while the second somatic pathogenic variant acquired in leukemic cells is typically in the region encoding the C-terminal (see <xref ref-type="sec" rid="cebpa-aml.Molecular_Genetics">Molecular Genetics</xref>).</p>
          <p>Note: In the literature, the terms <italic toggle="yes">CEBPA</italic>dm and <italic toggle="yes">CEBPA</italic>sm may be used. These terms refer to leukemic cells with a pathogenic variant in both copies of <italic toggle="yes">CEBPA</italic> (&#x02018;<italic toggle="yes">d</italic>ouble <italic toggle="yes">m</italic>utation&#x02019;) or in only one copy of <italic toggle="yes">CEBPA</italic> (&#x02018;<italic toggle="yes">s</italic>ingle <italic toggle="yes">m</italic>utation&#x02019;). These terms alone do not specify if the pathogenic variant is germline or somatic (see <xref ref-type="sec" rid="cebpa-aml.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>).</p>
          <p>Molecular testing approaches include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">CEBPA</italic> is performed in a non-leukemic specimen. Note: (1) Testing for a germline pathogenic variant should not be performed on blood or bone marrow during active AML. Testing a non-involved specimen, such as cells obtained by buccal swab/saliva, skin biopsy or cultured dendritic cells, is imperative. (2) It should be noted that <italic toggle="yes">CEBPA</italic> pathogenic variants are found in the leukemic cells of approximately 9% of persons with AML, including 15%-18% of persons with normal-karyotype AML [<xref ref-type="bibr" rid="cebpa-aml.REF.arber.2008">Arber et al 2008</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.renneville.2008.915">Renneville et al 2008</xref>]. However, few of these individuals have a germline <italic toggle="yes">CEBPA</italic> pathogenic variant. (3) Testing of blood or bone marrow during complete remission from AML may also be performed to detect germline variants. The percentage of residual leukemic cells in remission samples is negligible, ensuring that somatic variants are not falsely classified as germline variants.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">CEBPA</italic> and other genes of interest (see <xref ref-type="sec" rid="cebpa-aml.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included and sensitivity of multi-gene panels vary by laboratory and over time.</p>
            </list-item>
          </list>
          <table-wrap id="cebpa-aml.T.molecular_genetic_testing_us" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">CEBPA</italic>-Associated Familial Acute Myeloid Leukemia</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">CEBPA</italic>
                  </td>
                  <td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup><hr/></td>
                  <td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">100%&#x000a0;(11/11 families)&#x000a0;<sup>4,&#x000a0;5</sup><hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_cebpa-aml.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="cebpa-aml.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="cebpa-aml" object-id="cebpa-aml.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="cebpa-aml.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="cebpa-aml.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="cebpa-aml.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="cebpa-aml.TF.1.4">
                <label>4. </label>
                <p>Sequencing of the coding region does not detect putative partial or complete gene deletions or variants in promoter regions. However, no such germline variants causing familial AML with mutated <italic toggle="yes">CEBPA</italic> have been reported to date.</p>
              </fn>
              <fn id="cebpa-aml.TF.1.5">
                <label>5. </label>
                <p><xref ref-type="bibr" rid="cebpa-aml.REF.smith.2004.2403">Smith et al [2004]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.sellick.2005.1276">Sellick et al [2005]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2008.5088">Pabst et al [2008]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.renneville.2009.804">Renneville et al [2009]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.nanri.2010.237">Nanri et al [2010]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.stelljes.2011.1209">Stelljes et al [2011]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.taskesen.2011.2469">Taskesen et al [2011]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.xiao.2011.5257">Xiao et al [2011]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.debeljak.2013.e73">Debeljak et al [2013]</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.tawana.2015.1214">Tawana et al [2015]</xref></p>
              </fn>
              <fn id="cebpa-aml.TF.1.6">
                <label>6. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="cebpa-aml.TF.1.7">
                <label>7. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="cebpa-aml.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="cebpa-aml.Clinical_Description">
          <title>Clinical Description</title>
          <p>Germline <italic toggle="yes">CEBPA</italic> pathogenic variants were first associated with the autosomal dominant transmission of acute myeloid leukemia (AML) in 2004 [<xref ref-type="bibr" rid="cebpa-aml.REF.smith.2004.2403">Smith et al 2004</xref>]. Over the last decade, more than ten families have been reported, all manifesting a highly penetrant AML phenotype as described above. Given the limited number of individuals described in the literature, it is possible that the true range of clinical phenotypes may vary [<xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2009.5303">Pabst &#x00026; Mueller 2009</xref>] and ongoing investigation of this syndrome is essential.</p>
          <p>The age of onset of <italic toggle="yes">CEBPA</italic>-associated familial AML is variable, but appears to be earlier than sporadic AML. Disease onset has been reported in persons as young as 1.8 years [<xref ref-type="bibr" rid="cebpa-aml.REF.debeljak.2013.e73">Debeljak et al 2013</xref>] and older than 45 years [<xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2008.5088">Pabst et al 2008</xref>]. By contrast, the median age at diagnosis of persons with sporadic AML is 65 years.</p>
          <p>From an analysis of ten pedigrees with <italic toggle="yes">CEBPA</italic>-associated familial AML, the disease follows a course similar to sporadic AML with <italic toggle="yes">CEBPA</italic> pathogenic variants in both copies (<italic toggle="yes">CEBPA</italic>dm)<italic toggle="yes">.</italic> The prognosis of individuals with familial AML appears to be favorable, with ten-year overall survival (OS) reaching 67%, compared to 54% OS of younger adults with sporadic AML associated with two <italic toggle="yes">CEBPA</italic> pathogenic variants and 29% OS with sporadic AML associated with a single <italic toggle="yes">CEBPA</italic> pathogenic variant [<xref ref-type="bibr" rid="cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</xref>].</p>
          <p>Individuals with <italic toggle="yes">CEBPA</italic>-associated familial AML who have been cured of their initial disease may be at greater risk of developing recurrent, independent leukemic episodes that are characterized by a different somatic <italic toggle="yes">CEBPA</italic> pathogenic variant from that observed in the original tumor clone. This phenomenon contrasts with relapse in individuals with sporadic AML, where <italic toggle="yes">CEBPA</italic> pathogenic variants are stable throughout the disease course [<xref ref-type="bibr" rid="cebpa-aml.REF.tiesmeier.2003.413">Tiesmeier et al 2003</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.shih.2006.604">Shih et al 2006</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.hollink.2011.384">Hollink et al 2011</xref>].</p>
        </sec>
        <sec id="cebpa-aml.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>To date, the majority of germline <italic toggle="yes">CEBPA</italic> pathogenic variants are frameshift variants located in the N-terminal of the gene (preceding the internal start codon). Individuals commonly present with AML (of FAB subtypes M1, M2 or M4) following the acquisition of somatic <italic toggle="yes">CEBPA</italic> (and additional) pathogenic variants.</p>
        </sec>
        <sec id="cebpa-aml.Penetrance">
          <title>Penetrance</title>
          <p>Analysis of pedigrees reported to date suggests that germline <italic toggle="yes">CEBPA</italic> pathogenic variants exhibit high penetrance for the development of AML [<xref ref-type="bibr" rid="cebpa-aml.REF.nickels.2013.254">Nickels et al 2013</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</xref>]. The penetrance of pathogenic variants may vary within and between families; data from ten families with germline <italic toggle="yes">CEBPA</italic> pathogenic variants revealed that more than 80% of confirmed or presumed obligate adult heterozygotes have developed disease to date [<xref ref-type="bibr" rid="cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</xref>].</p>
        </sec>
        <sec id="cebpa-aml.Prevalence">
          <title>Prevalence</title>
          <p><italic toggle="yes">CEBPA-</italic>associated familial AML is very rare, with only eleven pedigrees reported as of this writing [<xref ref-type="bibr" rid="cebpa-aml.REF.smith.2004.2403">Smith et al 2004</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.sellick.2005.1276">Sellick et al 2005</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2008.5088">Pabst et al 2008</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.renneville.2009.804">Renneville et al 2009</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.nanri.2010.237">Nanri et al 2010</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.stelljes.2011.1209">Stelljes et al 2011</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.taskesen.2011.2469">Taskesen et al 2011</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.xiao.2011.5257">Xiao et al 2011</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.debeljak.2013.e73">Debeljak et al 2013</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</xref>].</p>
          <p>It has been suggested that 5%-10% of individuals with presumed sporadic <italic toggle="yes">CEBPA</italic>-associated AML, may have a germline <italic toggle="yes">CEBPA</italic> pathogenic variant. <xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2008.5088">Pabst et al [2008]</xref> reported that two of 18 individuals (11%) with <italic toggle="yes">CEBPA</italic>-associated AML had a germline <italic toggle="yes">CEBPA</italic> pathogenic variant and a family history of AML. A larger series reported by <xref ref-type="bibr" rid="cebpa-aml.REF.taskesen.2011.2469">Taskesen et al [2011]</xref> identified a germline <italic toggle="yes">CEBPA</italic> pathogenic variant in five of 71 individuals (7%); two of the five had a family history of AML.</p>
        </sec>
      </sec>
      <sec id="cebpa-aml.Genetically_Related_Allelic_Di">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with germline pathogenic variants in <italic toggle="yes">CEBPA</italic>.</p>
        <p>Note: Sporadic <italic toggle="yes">CEBPA-</italic>associated acute myeloid leukemia (AML) is defined as AML in which a somatic <italic toggle="yes">CEBPA</italic> pathogenic variant is acquired in leukemic cells alone and not in the germline (see <xref ref-type="sec" rid="cebpa-aml.Molecular_Genetics">Molecular Genetics</xref>). <italic toggle="yes">CEBPA</italic> has also been implicated in the solid tumors of individuals without AML [<xref ref-type="bibr" rid="cebpa-aml.REF.koschmieder.2009.619">Koschmieder et al 2009</xref>].</p>
      </sec>
      <sec id="cebpa-aml.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for <italic toggle="yes">CEBPA-</italic>associated familial acute myeloid leukemia (AML) includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sporadic AML with somatic mutation of <italic toggle="yes">CEBPA</italic></p>
          </list-item>
          <list-item>
            <p>AML secondary to environmental exposures (e.g., benzene, radiation, chemotherapy)</p>
          </list-item>
          <list-item>
            <p>Sporadic AML with more than one affected family memberNote: The more affected individuals in a family (and the closer the relationships) the greater the likelihood of a common cause.</p>
          </list-item>
        </list>
        <p>Note: AML is a relatively rare disease (~13,300 cases/year in the US); therefore, pedigrees with more than one individual with AML could have a heritable predisposition or a common exposure [<xref ref-type="bibr" rid="cebpa-aml.REF.owen.2008.123">Owen et al 2008</xref>].</p>
      </sec>
      <sec id="cebpa-aml.Management">
        <title>Management</title>
        <sec id="cebpa-aml.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis of <italic toggle="yes">CEBPA</italic>-Associated Familial AML</title>
          <p>To establish the extent of disease and needs of an individual newly diagnosed with AML, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Cardiac scan in individuals with a personal history of &#x02013; or signs and symptoms suspicious for &#x02013; heart disease and in those who have received previous anthracycline therapy</p>
            </list-item>
            <list-item>
              <p>HLA typing in anticipation of hematopoietic stem cell transplantation (HSCT)</p>
            </list-item>
            <list-item>
              <p>Lumbar puncture (LP) if symptoms suggest central nervous system disease. The timing of LP in AML is controversial.</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
          <p>Evaluation of an individual with a confirmed diagnosis of <italic toggle="yes">CEBPA</italic>-associated familial AML should include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Assembly of a detailed pedigree to identify additional affected individuals and potential carriers of the inherited pathogenic variant;</p>
            </list-item>
            <list-item>
              <p>Recommendation of consultation with a genetic counselor for all at-risk family members;</p>
            </list-item>
            <list-item>
              <p>Molecular testing of family members at risk using buccal, salivary or skin DNA. Peripheral blood DNA may also be used in individuals with no history of preceding hematologic disease and normal complete blood count (CBC).</p>
              <list list-type="bullet">
                <list-item>
                  <p>Comprehensive evaluation and screening of family members enables improved characterization of the clinical manifestations and penetrance within the pedigree.</p>
                </list-item>
                <list-item>
                  <p>Family members without the inherited pathogenic variant may be offered human leukocyte antigen (HLA) typing to assess their compatibility for stem cell donation to their affected relative.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: In all familial leukemia syndromes with a known inherited pathogenic variant, it is essential that screening of the pathogenic variant be performed in all relatives at risk prior to consideration of stem cell donation.</p>
        </sec>
        <sec id="cebpa-aml.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Management of <italic toggle="yes">CEBPA-</italic>associated familial AML does not differ from that of sporadic <italic toggle="yes">CEBPA-</italic>associated AML [<xref ref-type="bibr" rid="cebpa-aml.REF12">National Comprehensive Cancer Network 2009</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.d_hner.2010.453">D&#x000f6;hner et al 2010</xref>].</p>
          <p>Treatment usually includes cytarabine/anthracycline-based induction and cytarabine-based consolidation chemotherapy with or without HSCT according to clinical, cytogenetic, and molecular risk. For younger individuals with AML (even those without a clear family history), there is now increasing awareness that germline variants should be investigated and excluded prior to consideration of HSCT using sib/related donors. Specific treatment strategies are based on characteristics of the individual, response to chemotherapy, treatment setting, and protocol (if the individual is enrolled in a clinical trial). Note: Whenever possible, persons with AML should be treated as part of a clinical trial protocol.</p>
          <p>Relapses are treated with cytarabine-based salvage chemotherapy followed by allogeneic HSCT (if a suitable donor is available and if cure is the intent of treatment).</p>
        </sec>
        <sec id="cebpa-aml.Prevention_of_Secondary_Compli">
          <title>Prevention of Secondary Complications</title>
          <p>Prevention of secondary complications is similar to that for other types of AML:</p>
          <list list-type="bullet">
            <list-item>
              <p>Supportive care includes blood products such as red blood cell and platelet transfusions as needed and treatment of infections with antibiotics.</p>
            </list-item>
            <list-item>
              <p>Prophylactic antibiotics and antifungal agents are administered during periods of severe neutropenia including the consolidation and post-transplantation periods [<xref ref-type="bibr" rid="cebpa-aml.REF12">National Comprehensive Cancer Network 2009</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="cebpa-aml.Surveillance">
          <title>Surveillance</title>
          <p><bold>Affected individuals.</bold> Surveillance for <italic toggle="yes">CEBPA</italic>-associated familial AML is similar to that for other forms of AML. There are no generally accepted minimal residual disease (MRD) markers in <italic toggle="yes">CEBPA-</italic>associated AML or in most other AML subtypes with normal karyotypes.</p>
          <p>Individuals are monitored and evaluated in accordance with administered treatment, clinical course, symptoms, and protocol, if enrolled in clinical trials. When complete remission is achieved and intensification therapy is complete, individuals are monitored with:</p>
          <list list-type="bullet">
            <list-item>
              <p>CBC and platelet counts every one to three months for two years with the frequency decreasing to every three to six months for up to five years;</p>
            </list-item>
            <list-item>
              <p>Bone marrow aspiration when cytopenia and/or an abnormal peripheral blood smear are present.</p>
            </list-item>
          </list>
          <p>Note: The use of flow cytometry for MRD monitoring is controversial.</p>
          <p>Individuals with a germline <italic toggle="yes">CEBPA</italic> pathogenic variant who are cured of their initial disease episode may be at risk for new leukemic episodes, often occurring after a prolonged period of remission (&#x0003e;3 years post presentation) [<xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2009.1343">Pabst et al 2009</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.tawana.2015.1214">Tawana et al 2015</xref>]. In light of these data, lifelong clinical surveillance is warranted to ensure prompt recognition and appropriate management of disease recurrence. Repeat testing of <italic toggle="yes">CEBPA</italic> at recurrence is important to help distinguish conventional relapse from new, independent leukemic episodes.</p>
          <p><bold>Asymptomatic carriers.</bold> Asymptomatic individuals with a pathogenic <italic toggle="yes">CEBPA</italic> germline variant may be reviewed with CBC profiling every six to 12 months. Bone marrow examination may be performed if there is an appropriate clinical indication (e.g., abnormalities in CBC). Referral for post-testing genetic counseling should be considered as appropriate.</p>
        </sec>
        <sec id="cebpa-aml.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Use of sib or related donors for HSCT without prior assessment of the pathogenic germline variant in these individuals.</p>
        </sec>
        <sec id="cebpa-aml.Evaluation_of_Relatives_at_Ris">
          <title>Evaluation of Relatives at Risk</title>
          <p>To date, all individuals with germline pathogenic <italic toggle="yes">CEBPA</italic> variants have presented with overt AML without any preceding blood count abnormalities or myelodysplasia, this in contrast with other familial leukemia syndromes such as those associated with germline <italic toggle="yes">RUNX1</italic> or <italic toggle="yes">GATA2</italic> pathogenic variants [<xref ref-type="bibr" rid="cebpa-aml.REF.nickels.2013.254">Nickels et al 2013</xref>].</p>
          <p>The decision to test for an inherited pathogenic variant is ultimately governed by personal choice, the reassurance of regular clinical follow up, and provision of genetic counseling. It is noteworthy that clinical monitoring may enable earlier diagnosis (and treatment) of AML, hence minimizing the risks associated with delayed presentation (e.g., severe anemia, neutropenic sepsis, and severe hemorrhage), providing further rationale for molecular evaluation of at-risk relatives. There are currently no preemptive treatments available for asymptomatic carriers of a germline <italic toggle="yes">CEBPA</italic> pathogenic variant.</p>
          <p>See <xref ref-type="sec" rid="cebpa-aml.Related_Genetic_Counseling_Iss">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="cebpa-aml.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">Clinical Trials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="cebpa-aml.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="cebpa-aml.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Predisposition to <italic toggle="yes">CEBPA-</italic>associated familial acute myeloid leukemia (AML) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="cebpa-aml.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with <italic toggle="yes">CEBPA</italic>-associated familial AML have had an affected parent who shares the germline pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>In rare cases, a proband may have a <italic toggle="yes">de novo</italic> germline <italic toggle="yes">CEBPA</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of apparently asymptomatic parents of a proband with a germline pathogenic variant include a complete blood count (CBC) with hematologic indices, peripheral blood smear, and testing for the germline <italic toggle="yes">CEBPA</italic> pathogenic variant identified in the proband.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with <italic toggle="yes">CEBPA-</italic>associated familial AML may appear to be negative because of early death of a parent before the onset of AML or late onset of AML in a parent. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</p>
            </list-item>
            <list-item>
              <p>Note: If the parent is the individual in whom the germline pathogenic variant first occurred s/he could potentially have somatic mosaicism for the germline variant.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband has the germline <italic toggle="yes">CEBPA</italic> pathogenic variant, the risk to the sibs of inheriting the variant is 50%.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk for <italic toggle="yes">CEBPA-</italic>associated familial AML as the germline pathogenic variant may demonstrate differences in disease manifestation and latency across family members.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with <italic toggle="yes">CEBPA</italic>-associated familial AML has a 50% chance of inheriting the germline pathogenic variant.</p>
          <p><bold>Other family members.</bold> The risk of other family members inheriting the germline <italic toggle="yes">CEBPA</italic> pathogenic variant depends on the status of the proband's parents: if a parent is affected and/or has the germline pathogenic variant, his or her family members may be at risk.</p>
        </sec>
        <sec id="cebpa-aml.Related_Genetic_Counseling_Iss">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="cebpa-aml.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> If neither parent of a proband with <italic toggle="yes">CEBPA</italic>-associated familial AML has the pathogenic variant or clinical evidence of AML, the <italic toggle="yes">CEBPA</italic> pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p>
          <p><bold>Testing of at-risk asymptomatic family members.</bold> If a germline <italic toggle="yes">CEBPA</italic> pathogenic variant has been identified in a family member with AML, molecular genetic testing may be offered to at-risk family members in order to determine the need for clinical surveillance (see <xref ref-type="sec" rid="cebpa-aml.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</xref>).</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk in offspring of persons with known <italic toggle="yes">CEBPA</italic>-associated familial AML is before pregnancy. Because <italic toggle="yes">CEBPA</italic>-associated familial AML is rare, general screening of individuals with AML or a family history of AML for a <italic toggle="yes">CEBPA</italic> germline pathogenic variant is not recommended for family planning purposes unless <italic toggle="yes">CEBPA</italic>-associated familial AML is suspected.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
          <p>In AML generally, tissue banking that is performed for future research purposes should include banking of DNA, RNA, protein lysates, and cryopreserved cells.</p>
        </sec>
        <sec id="cebpa-aml.Prenatal_Testing_and_Preimplan">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once a germline <italic toggle="yes">CEBPA</italic> pathogenic variant has been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for <italic toggle="yes">CEBPA</italic>-associated familial AML are possible options.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="cebpa-aml.Resources">
        <title>Resources</title>
      </sec>
      <sec id="cebpa-aml.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="cebpa-aml.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><italic toggle="yes">CEBPA</italic> encodes the CCAAT/enhancer-binding protein alpha (C/EBP&#x003b1;), a transcription factor that plays a key role in granulocyte development. A detailed review of the role of C/EBP&#x003b1; in human cancer has been published [<xref ref-type="bibr" rid="cebpa-aml.REF.koschmieder.2009.619">Koschmieder et al 2009</xref>]. The role of mutation of <italic toggle="yes">CEBPA</italic> in the formation of acute myeloid leukemia (AML) is not well understood and is subject to ongoing research with several established mouse models simulating homozygous N- terminal frameshift mutations [<xref ref-type="bibr" rid="cebpa-aml.REF.kirstetter.2008.299">Kirstetter et al 2008</xref>], combined N- and C- terminal mutations [<xref ref-type="bibr" rid="cebpa-aml.REF.bereshchenko.2009.390">Bereshchenko et al 2009</xref>], or conditional loss of C/EBP&#x003b1; [<xref ref-type="bibr" rid="cebpa-aml.REF.ye.2013.385">Ye et al 2013</xref>].</p>
          <p>Note: The terms <italic toggle="yes">CEBPA</italic>dm and <italic toggle="yes">CEBPA</italic>sm are used in the literature and refer to leukemic cells with a pathogenic variant in both (&#x02018;double mutation&#x02019;) or in a single copy of <italic toggle="yes">CEBPA</italic> (&#x02018;single mutation&#x02019;), respectively. These terms do not indicate the location of variants within the gene or whether they are germline or somatic. As mentioned previously, the latter distinction is based upon the identification of pathogenic variants in non-leukemic DNA. In individuals with sporadic AML (caused by the somatic acquisition of <italic toggle="yes">CEBPA</italic> pathogenic variants), double and single mutated subtypes occur with approximately equal frequency. Notably, only double <italic toggle="yes">CEBPA</italic> mutations (predominantly combining N-terminal frameshift and C-terminal in-frame insertions or deletions) are associated with favorable prognostic significance [<xref ref-type="bibr" rid="cebpa-aml.REF.dufour.2010.570">Dufour et al 2010</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.green.2010.2739">Green et al 2010</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">CEBPA</italic> is a single-exon gene; the primary <italic toggle="yes">CEBPA</italic> transcript (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_004364.4">NM_004364.4</ext-link>) is 2631 bp. Initiation of translation at two in-frame AUG start codons (nucleotides 151-153 and 508-51) results in two C/EBP&#x003b1; protein isoforms. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="cebpa-aml" object-id="cebpa-aml.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign germline allelic variants.</bold> A few benign allelic variants in the <italic toggle="yes">CEBPA</italic> coding region have been reported (see <xref ref-type="table" rid="cebpa-aml.T.selected_cebpa_germline_alle">Table 2</xref>).</p>
          <p><bold>Pathogenic germline allelic variants.</bold> All reported pathogenic germline variants are small deletions, duplications, or insertions resulting in a frameshift causing premature truncation at the N-terminal region of the C/EBP&#x003b1; protein. The analytic sensitivity of sequence analysis is expected to be &#x0003e;99% for variants within the coding region. The germline variants identified to date are listed in <xref ref-type="table" rid="cebpa-aml.T.selected_cebpa_germline_alle">Table 2</xref>; the c.217_218insC variant has been reported in two pedigrees. Thus far, reported germline variants have been small insertions/deletions that result in frameshifts in <italic toggle="yes">CEBPA</italic> regions that encode the N-terminal region of the protein and predict premature termination of synthesis of the full-length C/EBP&#x003b1; protein (see <bold>Normal gene product</bold>).</p>
          <table-wrap id="cebpa-aml.T.selected_cebpa_germline_alle" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">CEBPA</italic> Germline Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                  <th id="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change <break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Benign</bold>
                    <hr/>
                  </td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.754G&#x0003e;T<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala252Ser<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_4" rowspan="9" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_004364.4">NM_004364.4</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_004355.2">NP_004355.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.713C&#x0003e;A<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala238Glu<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.690G&#x0003e;T<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr230=&#x000a0;<sup>2</sup><hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_1" rowspan="6" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.68delC<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro23ArgfsTer137<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.68dupC<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.His24AlafsTer84<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.141delC<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala48ProfsTer112<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.198_201dupCTAC<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ile68LeufsTer41<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.318_319dupT<hr/></td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp107ValfsTer54<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.217_218insC&#x000a0;<sup>3</sup><break/>(217insC)</td>
                  <td headers="hd_h_cebpa-aml.T.selected_cebpa_germline_alle_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe73SerfsTer35</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="cebpa-aml.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="cebpa-aml.TF.2.2">
                <label>2. </label>
                <p>Indicates that no effect on protein level is expected</p>
              </fn>
              <fn id="cebpa-aml.TF.2.3">
                <label>3. </label>
                <p>Reported in two pedigrees</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The use of alternative in-frame non-AUG (GUG) and AUG start codons results in protein isoforms with different lengths (see <related-object source-id="gene" document-id="cebpa-aml" object-id="cebpa-aml.molgen.TA">Table A</related-object>, <bold>Gene</bold>). When translation initiates from the AUG at nucleotides 151-153, isoform a (also known as C/EBP-42) is produced; it is a 42-kd transcription factor of 358 amino acids <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_004355.2">NP_004355.2</ext-link>. The full-length 42-kd protein contains two distinct N-terminal transactivation domains (mediate contact with transcriptional apparatus), a C-terminal basic region (DNA-binding), and a leucine zipper for dimerization.</p>
          <p>Alternatively, when translation initiates from the alternative start site at AUG at nucleotides 508-510, a 30-kd (also known as C/EBP-30) isoform b of 239 amino acids that lacks the first transactivation domain and impairs interaction with the transcriptional apparatus (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001272758.1">NP_001272758.1</ext-link>) is produced. The C-terminal domains are intact [<xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2007.6829">Pabst &#x00026; Mueller 2007</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2009.5303">Pabst &#x00026; Mueller 2009</xref>]. Evidence from cell culture identified C/EBP&#x003b1; protein as a tumor suppressor and an inhibitor of cell proliferation. Evidence from mouse models is consistent with the tumor suppressor activity being in the 42-kd isoform and transformation in the absence of 42 kd is mediated by a 30-kd isoform which has a dominant-negative effect leading to the formation of progenitors prone to deregulated proliferation and transformation [abstracted from <xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2009.5303">Pabst &#x00026; Mueller 2009</xref>].</p>
          <p><bold>Abnormal gene product.</bold> The reported germline pathogenic variants in <italic toggle="yes">CEBPA</italic> (<xref ref-type="table" rid="cebpa-aml.T.selected_cebpa_germline_alle">Table 2</xref>) occur before codon 120 and cause/predict premature termination of synthesis of the full-length C/EBP&#x003b1; protein, with preservation of the 30-kd isoform. The 30-kd protein is believed to inhibit the action of the normal 42-kd protein encoded by the remaining normal allele in a dominant-negative manner.</p>
          <p>
            <bold>Somatic <italic toggle="yes">CEBPA</italic> pathogenic variants</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>In <italic toggle="yes">CEBPA-</italic>associated familial AML.</bold> The leukemic cells of most individuals with <italic toggle="yes">CEBPA-</italic>associated familial AML are compound heterozygous. In addition to the germline pathogenic variant described above in the N-terminal region (see <bold>Pathogenic germline allelic variants</bold>), the leukemic cells commonly acquire somatic C-terminal in-frame pathogenic variant(s). Such variants disrupt the basic region and leucine zipper, impairing DNA binding as well as homo- and heterodimerization with other CEBP proteins and/or DNA binding [<xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2007.6829">Pabst &#x00026; Mueller 2007</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.pabst.2009.5303">Pabst &#x00026; Mueller 2009</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>In sporadic <italic toggle="yes">CEBPA-</italic>associated AML.</bold> This is defined as AML in which a somatic <italic toggle="yes">CEBPA</italic> pathogenic variant(s) is acquired in leukemic cells alone and not in the germline. In 45%-55% of all persons with sporadic <italic toggle="yes">CEBPA</italic>-associated AML<italic toggle="yes">,</italic> two pathogenic <italic toggle="yes">CEBPA</italic> variants are detected (<italic toggle="yes">CEBPA</italic>dm); most frequently, a frameshift N-terminal variant is combined with a C-terminal in-frame insertion or deletion [<xref ref-type="bibr" rid="cebpa-aml.REF.green.2010.2739">Green et al 2010</xref>, <xref ref-type="bibr" rid="cebpa-aml.REF.fasan.2014.794">Fasan et al 2014</xref>].</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="cebpa-aml.References">
        <title>References</title>
        <sec id="cebpa-aml.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="cebpa-aml.Literature_Cited.reflist0">
            <ref id="cebpa-aml.REF.arber.2008">
              <mixed-citation publication-type="book">Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4 ed. Lyon, France: WHO Press; 2008:110-23.</mixed-citation>
            </ref>
            <ref id="cebpa-aml.REF.bereshchenko.2009.390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bereshchenko</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilbao</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e5;nsson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luc</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grover</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobsen</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryder</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nerlov</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML.</article-title>
                <source>Cancer Cell.</source>
                <year>2009</year>
                <volume>16</volume>
                <fpage>390</fpage>
                <lpage>400</lpage>
                <pub-id pub-id-type="pmid">19878871</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.debeljak.2013.e73">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Debeljak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitanovski</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paji&#x0010d;</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jazbec</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Concordant acute myeloblastic leukemia in monozygotic twins with germline and shared somatic mutations in the gene for CCAAT-enhancer-binding protein &#x003b1; with 13 years difference at onset.</article-title>
                <source>Haematologica.</source>
                <year>2013</year>
                <volume>98</volume>
                <fpage>e73</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">23716546</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.d_hner.2010.453">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x000f6;hner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estey</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amadori</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appelbaum</surname>
                    <given-names>FR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000fc;chner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnett</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dombret</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenaux</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimwade</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larson</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lo-Coco</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naoe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niederwieser</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ossenkoppele</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sierra</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tallman</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f6;wenberg</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bloomfield</surname>
                    <given-names>CD</given-names>
                  </name>
                </person-group>
                <article-title>European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.</article-title>
                <source>Blood.</source>
                <year>2010</year>
                <volume>115</volume>
                <fpage>453</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">19880497</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.dufour.2010.570">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dufour</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metzeler</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoster</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zellmeier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benthaus</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauerland</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berdel</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000fc;chner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>W&#x000f6;rmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braess</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hiddemann</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohlander</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiekermann</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.</article-title>
                <source>J Clin Oncol.</source>
                <year>2010</year>
                <volume>28</volume>
                <fpage>570</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20038735</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.fasan.2014.794">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fasan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haferlach</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alpermann</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeromin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossmann</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eder</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weissmann</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dicker</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schindela</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kern</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haferlach</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schnittger</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>The role of different genetic subtypes of CEBPA mutated AML.</article-title>
                <source>Leukemia.</source>
                <year>2014</year>
                <volume>28</volume>
                <fpage>794</fpage>
                <lpage>803</lpage>
                <pub-id pub-id-type="pmid">24056881</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.green.2010.2739">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koo</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hills</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnett</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linch</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gale</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Prognostic Significance of CEBPA Mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.</article-title>
                <source>J Clin Oncol</source>
                <volume>28</volume>
                <fpage>2739</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">20439648</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.hollink.2011.384">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hollink</surname>
                    <given-names>IH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Heuvel-Eibrink</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arentsen-Peters</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimmermann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peeters</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valk</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balgobind</surname>
                    <given-names>BV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sonneveld</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaspers</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Bont</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trka</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baruchel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Creutzig</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pieters</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinhardt</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zwaan</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <article-title>Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.</article-title>
                <source>Haematologica.</source>
                <year>2011</year>
                <volume>96</volume>
                <fpage>384</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">21134981</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.kirstetter.2008.299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kirstetter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuster</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bereshchenko</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dvinge</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theilgaard-M&#x000f6;nch</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e5;nsson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedersen</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schrock</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porse</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobsen</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertone</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tenen</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nerlov</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.</article-title>
                <source>Cancer Cell.</source>
                <year>2008</year>
                <volume>13</volume>
                <fpage>299</fpage>
                <lpage>310</lpage>
                <pub-id pub-id-type="pmid">18394553</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.koschmieder.2009.619">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koschmieder</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balazs</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levantini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tenen</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Dysregulation of the C/EBP&#x003b1; differentiation pathway in human cancer.</article-title>
                <source>J Clin Oncol</source>
                <volume>27</volume>
                <fpage>619</fpage>
                <lpage>28</lpage>
                <pub-id pub-id-type="pmid">19075268</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.nanri.2010.237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nanri</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uike</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawakita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwanaga</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoshino</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsuya</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asou</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A family harboring a germ-line N-terminal C/EBP&#x003b1; mutation and development of acute myeloblastic leukemia with an additional somatic C-terminal C/EBP&#x003b1; mutation.</article-title>
                <source>Genes Chromosomes Cancer</source>
                <volume>49</volume>
                <fpage>237</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">19953636</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF12">
              <mixed-citation publication-type="webpage">National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology&#x02122;. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp">online</ext-link>. 2009. Accessed 4-26-13.</mixed-citation>
            </ref>
            <ref id="cebpa-aml.REF.nickels.2013.254">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nickels</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soodalter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Churpek</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Godley</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <article-title>Recognizing familial myeloid leukemia in adults.</article-title>
                <source>Ther Adv Hematol.</source>
                <year>2013</year>
                <volume>4</volume>
                <fpage>254</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">23926458</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.owen.2008.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Owen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnett</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgibbon</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Familial myelodysplasia and acute myeloid leukemia--a review.</article-title>
                <source>Br J Haematol.</source>
                <volume>140</volume>
                <fpage>123</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">18173751</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.pabst.2009.1343">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eyholzer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fos</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>BU</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.</article-title>
                <source>Br J Cancer</source>
                <volume>100</volume>
                <fpage>1343</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">19277035</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.pabst.2008.5088">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eyholzer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haefliger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schardt</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>BU</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.</article-title>
                <source>J Clin Oncol</source>
                <volume>26</volume>
                <fpage>5088</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">18768433</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.pabst.2007.6829">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>BU</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Transcriptional dysregulation during myeloid transformation in AML.</article-title>
                <source>Oncogene</source>
                <volume>26</volume>
                <fpage>6829</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">17934489</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.pabst.2009.5303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>BU</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia.</article-title>
                <source>Clin Cancer Res</source>
                <volume>15</volume>
                <fpage>5303</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19706798</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.renneville.2009.804">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Renneville</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mialou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philippe</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kagialis-Girard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biggio</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabot</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertrand</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preudhomme</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation.</article-title>
                <source>Leukemia.</source>
                <volume>23</volume>
                <fpage>804</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18946494</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.renneville.2008.915">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Renneville</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roumier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biggio</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nibourel</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boissel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenaux</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preudhomme</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Cooperating gene mutations in acute myeloid leukemia: a review of the literature.</article-title>
                <source>Leukemia</source>
                <volume>22</volume>
                <fpage>915</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">18288131</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.sellick.2005.1276">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sellick</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spendlove</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catovsky</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pritchard-Jones</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlston</surname>
                    <given-names>RS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukemia.</article-title>
                <source>Leukemia</source>
                <volume>19</volume>
                <fpage>1276</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15902292</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.shih.2006.604">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shih</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liang</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunn</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>TC</given-names>
                  </name>
                </person-group>
                <article-title>AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples.</article-title>
                <source>Leukemia.</source>
                <year>2006</year>
                <volume>20</volume>
                <fpage>604</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16453003</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.smith.2004.2403">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cavenagh</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lister</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgibbon</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutation of CEBPA in familial acute myeloid leukemia.</article-title>
                <source>N Engl J Med</source>
                <volume>351</volume>
                <fpage>2403</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15575056</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.stelljes.2011.1209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stelljes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corbacioglu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlenk</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000f6;hner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000fc;hwald</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossig</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehlert</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silling</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Tidow</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Juergens</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000f6;hner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berdel</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kienast</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koschmieder</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein &#x003b1; from hematopoietic cells in a family with AML.</article-title>
                <source>Leukemia.</source>
                <year>2011</year>
                <volume>25</volume>
                <fpage>1209</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">21455213</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.taskesen.2011.2469">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Taskesen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bullinger</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corbacioglu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanders</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erpelinck</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wouters</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Poel-van de Luytgaarde</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damm</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krauter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlenk</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f6;wenberg</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delwel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000f6;hner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valk</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000f6;hner</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.</article-title>
                <source>Blood.</source>
                <year>2011</year>
                <volume>117</volume>
                <fpage>2469</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">21177436</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.tawana.2015.1214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tawana</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renneville</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;d&#x000f6;r</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hills</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loveday</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Delft</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treleaven</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Georgiades</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uglow</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asou</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uike</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debeljak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jazbec</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ancliff</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gale</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mialou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000f6;hner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bullinger</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stelljes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlegelberger</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wozniak</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iqbal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okosun</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Araf</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frank</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lauridsen</surname>
                    <given-names>FB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porse</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nerlov</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dokal</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gribben</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preudhomme</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chelala</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cavenagh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgibbon</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Disease evolution and outcomes in familial AML with germline CEBPA mutations.</article-title>
                <source>Blood.</source>
                <year>2015</year>
                <volume>126</volume>
                <fpage>1214</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">26162409</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.tiesmeier.2003.413">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tiesmeier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czwalinna</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Tidow</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krauter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serve</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heil</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbeek</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.</article-title>
                <source>Br J Haematol.</source>
                <year>2003</year>
                <volume>123</volume>
                <fpage>413</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14616999</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.xiao.2011.5257">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Xiao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luo</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cai</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ye</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation.</article-title>
                <source>Blood.</source>
                <year>2011</year>
                <volume>117</volume>
                <fpage>5257</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">21403128</pub-id>
              </element-citation>
            </ref>
            <ref id="cebpa-aml.REF.ye.2013.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ye</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amabile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Staber</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levantini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberich-Jord&#x000e0;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawasaki</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tenen</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <article-title>C/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence.</article-title>
                <source>Nat Cell Biol.</source>
                <year>2013</year>
                <volume>15</volume>
                <fpage>385</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">23502316</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="cebpa-aml.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="cebpa-aml.Author_History">
          <title>Author History</title>
          <p>Jude Fitzgibbon, PhD (2016-present)Roger D Klein, MD, JD; Cleveland Clinic (2010-2016)Guido Marcucci, MD; Ohio State University (2010-2016)Kiran Tawana, MBChB, FRCPath (2016-present)</p>
        </sec>
        <sec id="cebpa-aml.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>28 April 2016 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 October 2010 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>30 December 2009 (rdk) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
